Biotechnology Jobs

• Warsaw, Poland
• Hybrid
• PLN 419,250 – PLN 698,750 pa
• Director

Provides medical and scientific leadership in pharmacovigilance and risk management for Respiratory, Inflammation and Immunology assets in clinical development. Interprets safety data, detects and escalates signals, and delivers evidence-based benefit-risk recommendations to senior governance. Leads Safety Review Teams and represents Safety on cross-functional clinical matrix teams in a global hybrid environment.

• Baar Onyx
• Hybrid
• US$189,750 – US$316,250 pa
• Director

Leads the design and execution of clinical biomarker and translational medicine strategies for late-stage oncology assets, defining patient segmentation and decision criteria within Clinical Matrix Teams. Validates predictive, pharmacodynamic and resistance biomarkers using platforms such as NGS, FISH, PCR, IHC/IF, flow cytometry, liquid biopsy/ctDNA and multi-omic analyses, and oversees sample testing plans and biomarker data packages for clinical and regulatory decisions.

NGS · FISH · PCR +6

• Waltham, United States
• Hybrid · 2 days in office
• US$242,250 – US$403,750 pa
• Director · manages people

Leads the global development of a medicine from clinical Proof of Concept through first major-market approval, acting as the single point of accountability. Builds and directs a matrixed Medicine Development Team spanning clinical, medical, commercial and manufacturing, and owns the asset's strategy, budget and governance decisions.

• London
• Hybrid · 2 days in office
• US$242,250 – US$403,750 pa
• Director · manages people

Leads the global development of a medicine from clinical Proof of Concept to approval in first major markets, acting as single point of accountability. Builds and directs a matrixed Medicine Development Team spanning clinical, medical, commercial and manufacturing, driving strategy, governance and go/no-go decisions. Hybrid role with at least two days per week on-site.

• Waltham, United States
• Hybrid
• £188,100 – £313,500 pa
• Director

Leads model-informed drug development for oncology programs, defining and executing model-based strategies from late discovery through lifecycle management. Conducts population PK, exposure-response, simulation-based trial design and dose selection, applying AI/ML, quantitative systems pharmacology and model-based meta-analysis. Presents to governance boards and regulators and works across matrix teams on small molecules, biologics and antibody drug conjugates.

NONMEM · R

• London
• Hybrid
• £119,250 – £198,750 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML and quantitative systems pharmacology methods, and defends results to governance boards and regulators. Sits within Oncology Translational Medicine's Clinical Pharmacology Modelling and Simulation group, working across small molecules, biologics and antibody drug conjugates.

NONMEM · R

• Belgium-Wavre
• Hybrid
• €119,250 – €198,750 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML, quantitative systems pharmacology and model-based meta-analysis to small molecules, biologics and antibody drug conjugates. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.

NONMEM · R

• USA - Pennsylvania - Upper Providence
• Hybrid
• US$188,100 – US$313,500 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work across small molecules, biologics and antibody drug conjugates, applying AI/ML and quantitative systems pharmacology methods. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.

NONMEM · R

• Durham Blackwell Street
• Hybrid
• US$188,100 – US$313,500 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML and quantitative systems pharmacology methods, and defends results to governance boards and regulators. Sits within a matrixed Clinical Pharmacology Modelling and Simulation group working across small molecules, biologics and antibody drug conjugates.

NONMEM · R

• USA - Pennsylvania - Upper Providence
• US$188,100 – US$313,500 pa
• Director

Leads quantitative systems pharmacology and QST modelling within a clinical pharmacology and quantitative medicine group, building mechanistic mathematical models of disease and drug action to inform trial design and MIDD strategy. Collaborates with biologists, clinicians, pharmacometricians and AI/ML teams, and represents the function on internal advisory boards.

• London
• Hybrid
• US$188,100 – US$313,500 pa
• Director
• Permanent

Leads quantitative systems pharmacology and QST modelling within a clinical pharmacology and quantitative medicine group, building mechanistic models of disease and drug action and running simulations to inform trial design. Defines and coordinates MIDD strategies across respiratory, immunology and inflammation programmes, working with biologists, clinicians, pharmacometricians and AI/ML specialists. The role sits in a newly formed centre of excellence and involves representing QSP on internal advisory boards.

• Durham Blackwell Street
• US$188,100 – US$313,500 pa
• Director

Leads quantitative systems pharmacology and QST modelling within a clinical pharmacology and quantitative medicine group, building mechanistic models of disease and drug action and running simulations to assess trial design. Defines and coordinates MIDD strategies across respiratory, immunology and inflammation programmes, working with biologists, clinicians, pharmacometricians and AI/ML specialists. The role sits in a newly established Centre of Excellence for model-informed drug development.

• Zug, Switzerland
• Hybrid · 2–3 days in office
• US$222,750 – US$371,250 pa
• Director

Serves as the physician within a clinical programme team, leading medical monitoring, safety oversight and data interpretation for GI oncology studies. Partners with a Senior Scientist and cross-functional matrix teams on protocol development, regulatory interactions and investigator engagement. Requires an on-site presence 2-3 days a week across UK, Swiss or US sites.

AI-enabled Insights

• Warsaw, Poland
• On-site
• US$284,250 – US$473,750 pa
• Director

Leads clinical development of GU oncology assets, designing and executing Phase 1-3 trials and serving as a core member of the Clinical Matrix Team. Provides real-time medical monitoring, safety review with pharmacovigilance, and authors clinical study reports and regulatory responses. Builds external expert relationships and contributes to business development diligence.

Real World Evidence (RWE)

• London
• On-site
• US$242,550 – US$404,250 pa
• Director · manages people

Senior physician leader providing medical oversight, safety monitoring and clinical data interpretation across lung cancer studies within a clinical programme team. Partners with the Senior Scientist and cross-functional groups on protocol design, regulatory interactions and external scientific engagement, while mentoring Medical Directors. Requires an on-site presence at least two days a week.